<DOC>
	<DOCNO>NCT01778413</DOCNO>
	<brief_summary>The main objective determine feasibility maintain virologic suppression standard plasma viral load dose reduction ATRIPLA ® .</brief_summary>
	<brief_title>Virological Immunological Safety Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine</brief_title>
	<detailed_description>The main objective study determine feasibility maintain virologic suppression standard plasma viral load ( limit detection 37 copy / mL ) dose reduction strategy ATRIPLA ® day three tablet per week patient infect HIV-1 sustain suppression plasma viral load standard two year .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Adults ( ≥ 18 year ) HIV1 infection , clinical stability , treatment ATRIPLA ® past two year . Standard plasma viral load limit detection least 2 year . CD4 count 350/mm3 time consideration study . Negative pregnancy test woman childbearing age , commitment acceptable contraceptive use least 2 week day 1 least 6 month last dose study drug . Patients give write informed consent In opinion investigator , able follow design protocol visit Patients experience virologic failure prior antiretroviral regimen Evidence previous mutation versus efavirenz , tenofovir emtricitabine Use chronic treatment plus ATRIPLA introduce 6 month prior entry patient study Any contraindication study drug Any condition ensure proper adherence study discretion attend physician patient Uncontrolled preexist psychiatric illness Any current sign alcoholism drug use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>